Dechra Pharmaceuticals Stock

DPH

GB0009633180

Market Closed - London S.E. Other stock markets 10:30:00 16/01/2024 +03			5-day change	1st Jan Change
3,866.00 ^GBX	-.--%		-.--%	-

06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI

Valuation: Dechra Pharmaceuticals

Market Cap	4.4B 5.81B 5.1B 4.71B 8.25B 548B 8.42B 56.59B 21.89B 271B 21.81B 21.34B 940B	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	4.83B 6.38B 5.6B 5.17B 9.05B 602B 9.25B 62.12B 24.03B 297B 23.94B 23.43B 1,032B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news : Dechra Pharmaceuticals

06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
03-31	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
03-11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
03-11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
13/10/25	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
13/10/25	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
03/09/25	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
18/08/25	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
17/06/25	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
05/05/25	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
05/05/25	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI
18/07/24	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.	CI

More news

Analysts' recommendations: Dechra Pharmaceuticals

27/06/23	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
27/06/23	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
27/06/23	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
07/03/23	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
12/01/23	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: Dechra Pharmaceuticals

27/12/23	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
30/10/23	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
17/10/23	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
17/10/23	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
07/09/23	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: Dechra Pharmaceuticals

12/01/24	BOLETÍN MATINAL : 12 de enero de 2024
13/12/23	Pharma und Gesundheit: weitere Konsolidierung
12/12/23	Farma en gezondheid: consolidatie gaat door
11/12/23	Farmaceutica e salute: continua il consolidamento
11/12/23	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: Dechra Pharmaceuticals

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	10/06/2024
Paul Sandland DFI	Director of Finance/CFO	46	03/04/2019
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	30/10/2019
Lawson Macartney BRD	Director/Board Member	68	01/12/2016
Lisa Bright BRD	Director/Board Member	59	01/02/2019

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

Income Statement and Estimates

More financial data

3 years	3,632	4,145.84
5 years	2,473.32	5,525
10 years	1,031	5,525

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/01/24	Paul Sandland	Free	Chief Financial Officer	2,293	0.0020%
15/01/24	Ian Page	Free	Chief Executive Officer	5,372	0.0047%
15/01/24	Paul Sandland	Free	Chief Financial Officer	2,335	0.0021%

	2022	2023
Net sales	682M 900M 790M 729M 1.28B 84.85B 1.3B 8.76B 3.39B 41.89B 3.38B 3.3B 146B	762M 1B 883M 814M 1.43B 94.77B 1.46B 9.79B 3.79B 46.79B 3.77B 3.69B 163B
Net income	58.2M 76.79M 67.45M 62.2M 109M 7.24B 111M 748M 289M 3.58B 288M 282M 12.43B	-27.9M -36.81M -32.33M -29.82M -52.26M -3.47B -53.38M -359M -139M -1.71B -138M -135M -5.96B
Net Debt	208M 275M 241M 222M 390M 25.91B 398M 2.68B 1.04B 12.79B 1.03B 1.01B 44.45B	430M 568M 498M 460M 806M 53.53B 823M 5.53B 2.14B 26.43B 2.13B 2.08B 91.83B

Dechra Pharmaceuticals Stock

Stocks

DPH

GB0009633180

Valuation: Dechra Pharmaceuticals

Latest news : Dechra Pharmaceuticals

Analysts' recommendations: Dechra Pharmaceuticals

Press Releases: Dechra Pharmaceuticals

News in other languages: Dechra Pharmaceuticals

Course Extremes

Managers and Directors: Dechra Pharmaceuticals

Latest insider transactions

Financials

Company Profile

Income Statement and Estimates